Cancer bispecific antibodies

Canevari, S., D. Mezzanzanica, A. Mazzoni, D.R. Negri, V. Ramakrishna, R.L. BoUinis, M.I. Colnaghi, and G. BoUs, Bispecific antibody targeted T cell therapy of ovarian cancer clinical results and future directions. J Hematother, 1995.4(5) 423-7. 

Recently, Sen et al. (2001) have described methods for generating highly effective HER-2-specific cytotoxic T cells by arming activated T cells with anti-CD3 X anti-HER-2 bispecific antibody. In this method OKT3 and 9184 anti-HER-2 monoclonal antibodies were conjugated and used to arm T cells that were subsequently tested for binding, cytotoxicity, and cytokine secretion assays. Armed T cells aggregate and selectively kill HER-2-positive breast cancer cells (MCF-7). 

Lewis, D., Cole, B. F., Wallace, P. K., Fisher, J. L., Waugh, N., Guyre, P. M., Fanger, M. W., Curnow, R. T., Kaufman, P. A., and Ernstoff, M. S. 2001. Pharmacokinetic-pharmacodynamic relationships of the bispecific antibody MDX-H210 when administered in combination with interferon gamma A multiple-dose phase-I study in patients with advanced cancer which overexpresses HER-2/wew. J. Immunol. Methods. 248 149-165. 

Van Ravenswaay Claasen, H. H., Van de Griend, R. J., Mezzanzanica, D. et al. 1993. Analysis of production, purification and cytolytic potential of bispecific antibodies reactive with ovarian-carcinoma-associated antigens and the T-cell antigen CD3. Int. J. Cancer 55 128-136. 

Lum LG, Davol PA, Lee RJ. The new face of bispecific antibodies targeting cancer and much more. Exp Hematol. 2006 34 1-6. 

B. J. Kroesen, W. Helfrich, G. Molema, and L. de Leij, Bispecific antibodies for treatment of cancer in experimental animal models and man, Adv. Drug Delivery Rev. 31 105-129 (1998). 

A variation thereof is the generation of bispecific antibodies [38]. In certain applications, these are designed to bind to a cancer-specific surface molecule with one binding domain, while the other binding domain recruits cytotoxic T cells to the pathogenic cell, inducing T-cell-dependent cytotoxicity [39]. 

The number of additional approaches using MAbs in experimental cancer therapy is very high, including bispecific antibodies, pro-drugs, and different forms of fragments and fusion proteins. In the prodrug approach, a non-toxic precursor mol-... 

A phase 11 study of the bispecific antibody MDX-H210 (anti-HER2xCD64) with GM-CSF in HER2 advanced prostate cancer. Br. J. Cancer 2001, 85, 152-156. 

Pullarkat Y Deo Y, Link J, Spears L, Marty V, Cumow R, Groshen S, Gee C, Weber JS A phase I study of a HER2/neu bispecific antibody with granulocyte-colony-stimulating factor in patients with metastatic breast cancer that overexpresses HER2/neu. Cancer Immunol Immunother 1999 ... 

Mezzanzanica, D., S. Canevari, S. Menard, S.M. Pnpa, E. Tagliabue, A. Lanzavecchia, and M.I. Colnaghi, Human ovarian carcinoma lysis by cytotoxic T cells targeted by bispecific monoclonal antibodies analysis of the antibody components. Int J Cancer, 1988. 41(4) 609-15. 

Kroesen, B.J., A. ter Haar, H. Spakman, P. Willemse, D.T. Sleijfer, E.G. de Vries, N.H. Mulder, H.H. Berendsen, PC. Limburg, T.H. The, et al.. Local antitumour treatment in carcinoma patients with bispecific-monoclonal-antibody-redirected T cells. Cancer Immunol Immunother, 1993.37(6) 400-7. 

Bivalent and Bispecific Monoclonal Antibodies in Cancer Therapy... 

Peltier, P. Curtet, C. Chatal, J.-F. Radioimmunodetection of medullary thyroid cancer using a bispecific anti-CEA/ Anti-insium-DTPA antibody and an indium-111 labeled DTPA-dimer. J. Nucl. Med. 1993, 34, 161- 113. 

Pimm MV, Robins RA, Embleton MJ, et al. A bispecific monoclonal antibody against methotrexate and a human tumor associated antigen augments cytotoxicity of methotrexate-carrier conjugate. Br J Cancer 1990 61 508-513. 

---